{"id":"vx-661-plus-ivacaftor-combination","safety":{"commonSideEffects":[{"rate":"null","effect":"Upper respiratory tract infection"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of VX-661 and ivacaftor works by correcting and potentiating the function of the CFTR protein, which is responsible for transporting chloride ions across cell membranes in the lungs, liver, pancreas, and intestine. This helps to improve the function of these organs and reduce the severity of cystic fibrosis symptoms.","oneSentence":"VX-661 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector, and ivacaftor is a CFTR potentiator.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:57.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis in patients with one or two copies of the F508del mutation"}]},"trialDetails":[{"nctId":"NCT04732910","phase":"","title":"Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2018-07-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT05743946","phase":"PHASE4","title":"Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-04-18","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":32},{"nctId":"NCT03587961","phase":"EARLY_PHASE1","title":"Personalized Theratyping Trial","status":"RECRUITING","sponsor":"George Solomon","startDate":"2019-08-01","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT07363304","phase":"","title":"Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-12-02","conditions":"Cystic Fibrosis (CF)","enrollment":150},{"nctId":"NCT05331183","phase":"PHASE3","title":"Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-11-23","conditions":"Cystic Fibrosis","enrollment":297},{"nctId":"NCT06457451","phase":"NA","title":"Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial","status":"RECRUITING","sponsor":"University Hospital, Tours","startDate":"2024-11-25","conditions":"Cystic Fibrosis","enrollment":100},{"nctId":"NCT05882357","phase":"PHASE3","title":"Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-06-27","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT06191640","phase":"","title":"Sinus Disease in Young Children With Cystic Fibrosis","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-04-12","conditions":"Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis)","enrollment":80},{"nctId":"NCT04969224","phase":"PHASE3","title":"A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-12","conditions":"Cystic Fibrosis","enrollment":82},{"nctId":"NCT03525574","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-09","conditions":"Cystic Fibrosis","enrollment":507},{"nctId":"NCT02070744","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2014-03","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT03506061","phase":"PHASE2","title":"Trikafta in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-04","conditions":"Cystic Fibrosis","enrollment":42},{"nctId":"NCT07148739","phase":"PHASE4","title":"Ensuring Access to Optimal Therapy in CF: The ENACT Study","status":"RECRUITING","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2025-06-10","conditions":"Cystic Fibrosis (CF)","enrollment":95},{"nctId":"NCT04183790","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-17","conditions":"Cystic Fibrosis","enrollment":64},{"nctId":"NCT03624101","phase":"PHASE4","title":"Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2018-12-01","conditions":"Cystic Fibrosis","enrollment":1},{"nctId":"NCT05279040","phase":"","title":"Trikafta Exercise Study in Cystic Fibrosis","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-10","conditions":"Cystic Fibrosis, Lung Diseases","enrollment":20},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":"Cystic Fibrosis","enrollment":435},{"nctId":"NCT04509050","phase":"","title":"Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children","status":"RECRUITING","sponsor":"Sonya Heltshe","startDate":"2020-11-18","conditions":"Cystic Fibrosis","enrollment":210},{"nctId":"NCT05274269","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-09","conditions":"Cystic Fibrosis","enrollment":307},{"nctId":"NCT05076149","phase":"PHASE3","title":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-27","conditions":"Cystic Fibrosis","enrollment":597},{"nctId":"NCT04618185","phase":"","title":"Gut Imaging for Function & Transit in CF - GIFT-CF 3","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2020-10-21","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT04545515","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-11","conditions":"Cystic Fibrosis","enrollment":120},{"nctId":"NCT04602468","phase":"PHASE4","title":"Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Royal College of Surgeons, Ireland","startDate":"2020-09-03","conditions":"Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children","enrollment":237},{"nctId":"NCT03537651","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-04-25","conditions":"Cystic Fibrosis","enrollment":130},{"nctId":"NCT04058366","phase":"PHASE3","title":"Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-12-05","conditions":"Cystic Fibrosis","enrollment":251},{"nctId":"NCT04415268","phase":"NA","title":"Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Universidad Europea de Madrid","startDate":"2020-06-09","conditions":"Cystic Fibrosis in Children","enrollment":""},{"nctId":"NCT02565914","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":1131},{"nctId":"NCT04599465","phase":"PHASE3","title":"A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-15","conditions":"Cystic Fibrosis","enrollment":69},{"nctId":"NCT05111145","phase":"PHASE3","title":"A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-14","conditions":"Cystic Fibrosis","enrollment":86},{"nctId":"NCT05937815","phase":"NA","title":"Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-13","conditions":"Cystic Fibrosis","enrollment":253},{"nctId":"NCT04043806","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-09","conditions":"Cystic Fibrosis","enrollment":458},{"nctId":"NCT04006873","phase":"PHASE2","title":"Gut Imaging for Function & Transit in Cystic Fibrosis Study 2","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2019-09-03","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT03912233","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-04-30","conditions":"Cystic Fibrosis","enrollment":87},{"nctId":"NCT05699148","phase":"","title":"Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior","status":"UNKNOWN","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-04-01","conditions":"Cystic Fibrosis","enrollment":17},{"nctId":"NCT05576324","phase":"","title":"Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-12-30","conditions":"Cystic Fibrosis","enrollment":130},{"nctId":"NCT04353817","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-06-19","conditions":"Cystic Fibrosis","enrollment":121},{"nctId":"NCT03768089","phase":"PHASE1, PHASE2","title":"Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-20","conditions":"Cystic Fibrosis","enrollment":115},{"nctId":"NCT03447262","phase":"PHASE3","title":"A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-07-13","conditions":"Cystic Fibrosis","enrollment":484},{"nctId":"NCT05200429","phase":"","title":"Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT03227471","phase":"PHASE1, PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":"Cystic Fibrosis","enrollment":225},{"nctId":"NCT02508207","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-02","conditions":"Cystic Fibrosis","enrollment":34},{"nctId":"NCT04702360","phase":"","title":"ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT04058353","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-28","conditions":"Cystic Fibrosis","enrollment":271},{"nctId":"NCT03224351","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-08-08","conditions":"Cystic Fibrosis","enrollment":124},{"nctId":"NCT04056702","phase":"","title":"Impact of Triple Combination CFTR Therapy on Sinus Disease.","status":"UNKNOWN","sponsor":"Jennifer Taylor-Cousar","startDate":"2019-09-05","conditions":"Cystic Fibrosis","enrollment":31},{"nctId":"NCT04038710","phase":"","title":"Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2019-09-05","conditions":"Cystic Fibrosis","enrollment":8},{"nctId":"NCT02951195","phase":"PHASE2","title":"A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-11","conditions":"Cystic Fibrosis","enrollment":80},{"nctId":"NCT02951182","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-10","conditions":"Cystic Fibrosis","enrollment":74},{"nctId":"NCT03525444","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-06-15","conditions":"Cystic Fibrosis","enrollment":405},{"nctId":"NCT03140527","phase":"PHASE1","title":"Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Proteostasis Therapeutics, Inc.","startDate":"2017-04-10","conditions":"Healthy Volunteer, Cystic Fibrosis","enrollment":171},{"nctId":"NCT03447249","phase":"PHASE3","title":"A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-07","conditions":"Cystic Fibrosis","enrollment":385},{"nctId":"NCT02953314","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-11","conditions":"Cystic Fibrosis","enrollment":83},{"nctId":"NCT03559062","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-05-17","conditions":"Cystic Fibrosis","enrollment":67},{"nctId":"NCT03525548","phase":"PHASE3","title":"A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-08-03","conditions":"Cystic Fibrosis","enrollment":113},{"nctId":"NCT04058210","phase":"","title":"VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT02730208","phase":"PHASE2","title":"A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-09","conditions":"Cystic Fibrosis","enrollment":41},{"nctId":"NCT03460990","phase":"PHASE3","title":"A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-05-01","conditions":"Cystic Fibrosis","enrollment":116},{"nctId":"NCT03150719","phase":"PHASE3","title":"A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-05-24","conditions":"Cystic Fibrosis","enrollment":98},{"nctId":"NCT02412111","phase":"PHASE3","title":"A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-06","conditions":"Cystic Fibrosis","enrollment":156},{"nctId":"NCT03278314","phase":"","title":"Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT02392234","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-03","conditions":"Cystic Fibrosis","enrollment":248},{"nctId":"NCT02347657","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-01","conditions":"Cystic Fibrosis","enrollment":510},{"nctId":"NCT02516410","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":168},{"nctId":"NCT01531673","phase":"PHASE2","title":"Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Cystic Fibrosis","enrollment":194},{"nctId":"NCT03486236","phase":"PHASE1","title":"A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-07-20","conditions":"Cystic Fibrosis","enrollment":16},{"nctId":"NCT03029455","phase":"PHASE1","title":"A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-11","conditions":"Cystic Fibrosis","enrollment":163},{"nctId":"NCT02015507","phase":"PHASE1","title":"An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2014-01","conditions":"Cystic Fibrosis","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VX-661 plus ivacaftor combination","genericName":"VX-661 plus ivacaftor combination","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VX-661 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector, and ivacaftor is a CFTR potentiator. Used for Cystic fibrosis in patients with one or two copies of the F508del mutation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}